Ascentage Pharma Group International

AAPGVOTCHealthcare

$17.38

+$0.13(+0.75%)

Market Cap$127308500

P/E Ratio—

52W High$18.0

52W Low$16.5

Avg Volume498K

Open$17.25

Beta1.10

Free Cash Flow Financials Revenue

Ascentage Pharma Group International (AAPGV) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

AAPGV · free cash flow · updated Jun 15, 2026

Core FCF metrics

AAPGV · FCF · TTM · margin & CAGR

Free cash flow was −$135.6M for FY2024 (fiscal year ending 2024-12-31), up 82.7% year-over-year The FCF margin was -13.8%.

FY2024 Free Cash Flow−$135.6M▲ +82.7% YoY

Trailing 12M (TTM)−$61.8Mtrailing 4 quarters sum

FCF Margin-13.8%−$135.6M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 15, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

AAPGV · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2024Latest−$111.4M(24M)−$135.6M▲ +82.7%-13.8%

FY2023−$726.1M(57M)−$782.9M▲ +12.1%-352.7%

FY2022−$653.9M(237M)−$890.9M▲ +14.4%-424.8%

FY2021−$604.7M(437M)−$1.04B▼ 20.9%—

FY2020−$610.0M(251M)−$861.4M▼ 59.0%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

AAPGV · P/FCF · FCF yield · FCF per share

Ascentage Pharma Group International (AAPGV) reported negative free cash flow of −$0.14B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2024 · 2024-12-31

Cash flow statement summary

AAPGV · cash flow statement · operating / investing / financing

For FY2024, Ascentage Pharma Group International generated −$111.4M in operating cash flow and spent 24M in capital expenditures, yielding −$135.6M in free cash flow.

Operating Activities

−$111.4M

Cash from core business operations

2024-12-31

Investing Activities

−$362.0M

CapEx, acquisitions & investments

2024-12-31

Financing Activities

+$314.8M

Buybacks, dividends & debt

2024-12-31

FCF FormulaOperating CF (−$111.4M) − |CapEx| (24M) = FCF (−$135.6M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

AAPGV vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Ascentage Pharma Group InternationalYOU

AAPGV

−$135.6M+82.7%-13.8%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Ascentage Pharma Group International (AAPGV) reported free cash flow of −$135.6M for FY2024 (fiscal year ending 2024-12-31), up 82.7% year-over-year. The FCF margin was -13.8%.

Ascentage Pharma Group International has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 9 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

AAPGV free cash flow · 8 questions

Ascentage Pharma Group International free cash flow was −$135.6M for FY2024, up 82.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$61.8M.

AAPGV free cash flowAAPGV FCFAAPGV FCF 2024AAPGV free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Ascentage Pharma Group International · Ascentage Pharma Group International SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 15, 2026